Legislative Documents

Also, variously referred to as: House bills; House documents; House legislative documents; legislative documents; General Court documents

Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats - Fig 1

<p><b>Product ion spectra of DAS, a) and ERL, b)</b>.</p

Evaluation of the extraction efficiency and matrix effect for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.

<p>Evaluation of the extraction efficiency and matrix effect for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.</p

LC–MS/MS optimized parameters for the determination of the studied drugs.

<p>LC–MS/MS optimized parameters for the determination of the studied drugs.</p

Regression and statistical parameters for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.

<p>Regression and statistical parameters for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.</p

Main pharmacokinetic parameters (mean±SD) after oral administration of DAS (25 mg/kg) to rats (<i>n</i> = 5).

<p>Main pharmacokinetic parameters (mean±SD) after oral administration of DAS (25 mg/kg) to rats (<i>n</i> = 5).</p

Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats - Fig 3

<p><b>Plasma concentration–time profile of DAS in rats after an oral administration of a combination of DAS (25 mg/kg) following the administration of DAS (25 mg/kg) alone or when co-administered with either curcumin preparations I, II, a), olive oil, I, II, b), or cocoa extract preparations I, II, c)</b>.</p

Evaluation of the intra-day and inter-day accuracy and precision for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.

<p>Evaluation of the intra-day and inter-day accuracy and precision for the determination of DAS in rat plasma by the proposed UPLC-MS/MS method.</p

Evaluation of the dilution integrity of DAS in rat plasma.

<p>Evaluation of the dilution integrity of DAS in rat plasma.</p

Appropriateness of anemia management in hemodialysis patients

AbstractThe anemia of end stage renal disease (ESRD) is common and often severe complication that can be managed successfully by erythropoiesis-stimulating agents (ESA) administration.AimsTo investigate current practice of anemia management in hemodialysis patients and to assess the appropriateness of anemia management by comparing observed practice to the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline recommendations.Settings and designThe study was conducted at two hemodialysis centers in Riyadh, Saudi Arabia. Data on anemia parameters, comorbidities, ESA dosing and iron supplementation were collected. The data were collected for 7 months retrospectively from April to the end of May 2008 and prospectively from June to October 2008. Patients who were over 18 years of age with ESRD undergoing hemodialysis were included. Patients were excluded if they have cancer or receiving chemotherapy or radiotherapy.ResultsData were collected from 87 patients. Mean Hgb value for those patients was 11.16±0.97g/dL. Thirty-nine patients (45%) had mean Hgb values between 11.0 and 12.0g/dL the target range recommended by KDOQI guideline. The mean weekly prescribed dose of erythropoietin was 8099±5946IU/Week (135±99IU/kg/Week). Information on ferritin concentrations was available for 48 (55%) patients. The mean serum ferritin concentration for those patients was 693±420.5ng/mL. Fifty-two patients had transferrin saturation (TSAT) values recorded. The mean TSAT value was 38.5±19.7%. Conclusions: There is an opportunity to improve anemia management in hemodialysis patients particularly thorough evaluation of causes of inadequate response rate and better monitoring and management of iron status